Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 759 of 1,261
  1. US 9000041

    Hydroxyl compounds and compositions for cholesterol management and related uses

    Esperion Therapeutics, Inc. · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  2. US 9000025

    Autotaxin inhibitors and uses thereof

    AMIRA PHARMACEUTICALS, INC. · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  3. US 9000020

    Linked dibenzimidazole antivirals

    Enanta Pharmaceuticals, Inc. · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  4. US 8999988

    Protein kinase inhibitors

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  5. US 8999996

    Hydrazide containing nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  6. US 8999934

    Treatment of astrocytes-tumor cells inhibitors of endothelin receptors

    The Board of Regents of the University of Texas System · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  7. US 8999947

    Nucleic acid functionalized nanoparticles for therapeutic applications

    Northwestern University · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  8. US 8999638

    Method of treatment based on polymorphisms of the KCNQ1 gene

    VANDA PHARMACEUTICALS INC. · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  9. US 8999976

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  10. US 8999349

    HMGB1-derived peptides enhance immune response to antigens

    The Regents of the University of California · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  11. US 8999294

    Nanoparticles for use in tumor diagnosis and therapy

    The Board of Regents of the University of Texas System · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  12. US 8999351

    Lipids and compositions for the delivery of therapeutics

    Tekmira Pharmaceuticals Corporation · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  13. US 8998847

    Drug releasing coatings for medical devices

    Lutonix, Inc. · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  14. US 8998846

    Drug releasing coatings for balloon catheters

    Lutonix, Inc. · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  15. US 9000040

    Cross-linked fatty acid-based biomaterials

    ATRIUM MEDICAL CORPORATION · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  16. US 9000191

    Serotonin reuptake inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  17. US 9000143

    Compositions and methods for inhibiting expression of IKK-B gene

    Alnylam Pharmaceuticals, Inc. · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  18. US 9000131

    Antibodies that neutralize botulinum neurotoxins

    The Regents of the University of California · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted
  19. EP 2852409

    KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS

    GANYMED PHARMACEUTICALS AG [DE] · Granted Apr 1, 2015 · Expires Mar 27, 2035

    granted
  20. US 8993633

    Treatment of muscle disease characterized by insulin resistance

    Fate Therapeutics, (Canada) Inc. · Granted Mar 31, 2015 · Expires Mar 26, 2035

    granted
  21. US 8993585

    Cyclic amine substituted pyrimidinediamines as PKC inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Mar 31, 2015 · Expires Mar 26, 2035

    granted
  22. US 8992902

    N-maleimidyl polymer derivatives

    Nektar Therapeutics · Granted Mar 31, 2015 · Expires Mar 26, 2035

    granted
  23. US 8993548

    Natural combination hormone replacement formulations and therapies

    Compass Therapeutics LLC · Granted Mar 31, 2015 · Expires Mar 26, 2035

    granted
  24. US 8993549

    Natural combination hormone replacement formulations and therapies

    Compass Therapeutics LLC · Granted Mar 31, 2015 · Expires Mar 26, 2035

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.